Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Everest Medicines Reports In-licensed Candidate Effective for Rare Kidney Disease

publication date: Jun 22, 2023

Shanghai Everest Medicines reported that a partnered rare disease drug, a treatment for the kidney disease,  IgA nephropathy (IgAN), was effective in a Phase III trial conducted by Sweden’s Calliditas Therapeutics. In 2019, Everest entered a $121 million deal for China rights to Nefecon from Calliditas. Nefecon is an oral delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity. The results of the Phase III trial showed a statistically significant improvement compared to placebo. Everest said it expects to release data from a cohort of China patients in Q3 of 2023. More details....

Stock Symbols: (HK: 1952) (NSDQ: CALT)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital